The non-interventional trial was always independent of the interventional trial. It was also never designed to show bisantrene-specific insights. The purpose of the trial was to collect critical control data needed to maximise the clinical and commercial value of the breast cancer bisantrene cardioprotection trial.
While there have always been external datasets that can answer some important questions (and these were used), there were other questions of critical importance that could not be answered using the historical datasets. I look forward to learning how these questions can now be answered from the historical datasets when the strategic update is released.
- Forums
- ASX - By Stock
- RAC
- Ann: H1 2023 Preclinical and Clinical Programs Update
Ann: H1 2023 Preclinical and Clinical Programs Update, page-72
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
$1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 51 | $1.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.60 | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 54981 | 1.550 |
1 | 700 | 1.520 |
1 | 2750 | 1.510 |
3 | 7984 | 1.505 |
5 | 17550 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.600 | 20000 | 1 |
1.620 | 2000 | 1 |
1.685 | 5000 | 1 |
1.690 | 6570 | 3 |
1.695 | 7731 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |